Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups

Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups

We describe the results of two vaccinations of a self-experimenting healthy volunteer with SARS-CoV-2-derived peptides performed in March and April 2020, respectively. The first set of peptides contained eight peptides predicted to bind to the individual’s HLA molecules. The second set consisted of...

Full description

Bibliographic Details
Main Authors: Hans-Georg Rammensee, Cécile Gouttefangeas, Sonja Heidu, Reinhild Klein, Beate Preuß, Juliane Sarah Walz, Annika Nelde, Sebastian P. Haen, Michael Reth, Jianying Yang, Ghazaleh Tabatabai, Hans Bösmüller, Helen Hoffmann, Michael Schindler, Oliver Planz, Karl-Heinz Wiesmüller, Markus W. Löffler
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Vaccines
Subjects:
peptide vaccine
adjuvant
lipopeptide
high-risk patient
COVID-19
SARS-CoV-2
Online Access:https://www.mdpi.com/2076-393X/9/5/428

Internet

https://www.mdpi.com/2076-393X/9/5/428

Similar Items